Is CymaBay Therapeutics a good investment?
John Parsons
Updated on February 08, 2026
Is CymaBay Therapeutics a good investment?
CymaBay Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Who owns Cbay stock?
Top 10 Owners of Cymabay Therapeutics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 4.73% | 3,260,821 |
| Baker Bros. Advisors LP | 3.15% | 2,170,464 |
| Millennium Management LLC | 2.98% | 2,053,779 |
| Citadel Advisors LLC | 2.29% | 1,580,975 |
Is Cbay a buy or sell?
Out of 3 analysts, 2 (66.67%) are recommending CBAY as a Strong Buy, 1 (33.33%) are recommending CBAY as a Buy, 0 (0%) are recommending CBAY as a Hold, 0 (0%) are recommending CBAY as a Sell, and 0 (0%) are recommending CBAY as a Strong Sell. What is CBAY’s earnings growth forecast for 2021-2023?
Is Cbay a buy Zacks?
– CBAY – Stock Price Today – Zacks….(Delayed Data from NSDQ)
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 25.60% |
| 2 | Buy | 19.21% |
| 3 | Hold | 10.85% |
| 4 | Sell | 6.62% |
What is the stock price of CymaBay Therapeutics?
This stock option grant has an exercise price of $4.37 per share, which is equal to the closing price of CymaBay’s common stock on May 17, 2021, the date of grant for the stock option.
Where is the mailing address for CymaBay Therapeutics?
CymaBay Therapeutics’ mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]
What is the consensus rating for CymaBay Therapeutics?
CymaBay Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings. Price Target Upside/Downside. According to analysts’ consensus price target of $11.18, CymaBay Therapeutics has a forecasted upside of 164.3% from its current price of $4.23.
What kind of disease does CymaBay Therapeutics treat?
1. According to Zacks Investment Research, “CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company’s lead product candidate, arhalofenate, is being developed for the treatment of gout.
This stock option grant has an exercise price of $4.37 per share, which is equal to the closing price of CymaBay’s common stock on May 17, 2021, the date of grant for the stock option.
1. According to Zacks Investment Research, “CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company’s lead product candidate, arhalofenate, is being developed for the treatment of gout.
CymaBay Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings. Price Target Upside/Downside. According to analysts’ consensus price target of $11.18, CymaBay Therapeutics has a forecasted upside of 164.3% from its current price of $4.23.
CymaBay Therapeutics’ mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]
